论文部分内容阅读
目的 比较CAF与CA方案在治疗晚期发生转移的乳腺癌中的疗效及毒副作用。方法 75例患者接受CA方案治疗 ,CTX60 0mg/m2 静推第 1天 ,ADM 60mg/m2 静推第 2天。另外 75例接受CAF方案治疗 ,CTX 60 0mg/m2 静推第 1天 ,ADM 60mg/m2 静推第 2天 ,5 -Fu 5 0 0mg/m2 静脉滴注第 1～ 5天。均应用 3周期以上。结果 CA方案的缓解率与CAF方案的缓解率无明显差异 (CA为 5 0 67% ,CAF为 5 8 63 % ,P >0 0 5 )。中位生存期两组相似。毒副作用都能耐受。CA方案胃肠道反应较CAF轻。结论 CA方案与CAF方案均是治疗晚期乳腺癌的较佳方案 ,对晚乳腺癌有较高的缓解率和较低的毒副作用。
Objective To compare the efficacy and side effects of CAF and CA regimens in the treatment of metastatic breast cancer. Methods Seventy-five patients underwent CA regimen, CTX60 0mg/m2 intravenously on the first day, and ADM 60mg/m2 on the second day. Another 75 patients were treated with CAF regimen, CTX 60 mg/m2 on the first day of intravenous infusion, ADM 60 mg/m2 on the second day of intravenous infusion, and 5-Fu 500 mg/m2 infusion on the first to fifth days. Apply more than 3 cycles. Results There was no significant difference between the remission rate of the CA program and the remission rate of the CAF program (CA was 5067%, CAF was 5836.3%, P > 0 05). The median survival was similar in both groups. Toxic side effects can tolerate. The CA regimen is less gastrointestinal than CAF. Conclusion Both CA regimen and CAF regimen are the better options for the treatment of advanced breast cancer, with higher remission rate and lower side effects on late breast cancer.